Last updated: July 27, 2023
Sponsor: RenJi Hospital
Overall Status: Active - Recruiting
Phase
N/A
Condition
Lymphoproliferative Disorders
Multiple Myeloma
Leukemia
Treatment
Oral Nutritional Supplement
Traditional Control
Clinical Study ID
NCT05460013
2021-M05
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Planned for HSCT
- No contraindications to enteral nutrition
- Able to consent
Exclusion
Exclusion Criteria:
- Existing contraindications to enteral nutrition
- Existing infectious diarrhoea
- Had other malignancies
- Had gut surgery in a year
- Had used prebiotics or probiotics or synbiotic in a month
- Immunosuppressive OR prolonged corticosteroid therapy (more than three months)
- Chronic kidney disease (eGFR < 60 mL/min/1.73m2)
- Pregnancy or lactation
- Had an allergy, or intolerance to ingredients of dietary supplements
- Judged to be unsafe to tolerate fiber
Study Design
Total Participants: 100
Treatment Group(s): 2
Primary Treatment: Oral Nutritional Supplement
Phase:
Study Start date:
August 01, 2022
Estimated Completion Date:
December 31, 2024
Study Description
Connect with a study center
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai 200124
ChinaActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.